Paying a high premium for Novo Nordisk stock may be justifiable based on the company's significant growth opportunities.Novo Nordisk (NVO -8.37%) is a big name in diabetes care and weight loss. And that's the primary reason people invest in the business today: the lucrative opportunities it has in those areas of healthcare.But the company's drugs have the potential to help people with even more conditions. That's why, although some investors might see it as expensive, I think the stock may be undervalued. T ...